Premium
Phase II study of high‐dose tamoxifen (NSC‐180973) in patients with disseminated malignant melanoma
Author(s) -
Creagan Edward T.,
Ingle James N.,
Ahmann David L.,
Green Stephanie J.
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19820401)49:7<1353::aid-cncr2820490707>3.0.co;2-4
Subject(s) - medicine , melanoma , nausea , tamoxifen , chemotherapy , regimen , oncology , progressive disease , cancer , gastroenterology , breast cancer , cancer research
Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen, 100 mg/m 2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reassessment. Moderate to severe nausea occurred in 24% of patients. In the dose and schedule used in this study, tamoxifen is ineffective in patients with advanced malignant melanoma and prior chemotherapy exposure.